Polaris Partners

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.

Engine Biosciences is a biotech company focused on revolutionizing drug discovery through the application of machine learning and network biomedicine. Based in San Francisco and Asia, the company has developed a proprietary platform that combines high-throughput wet lab experimentation with advanced artificial intelligence algorithms. This platform is designed to map and analyze complex biological networks, generating unique data on gene interactions and providing insights validated through controlled experiments. By doing so, Engine Biosciences aims to accelerate research and development processes and reduce costs associated with creating new medical therapies. The company collaborates with various partners and actively applies its technology to address a range of disease indications, leveraging the expertise of its scientific leadership team, which includes faculty members from renowned institutions such as MIT, Harvard, and the Mayo Clinic.

65LAB focuses on scientific advancement to create new therapeutic companies and lifesaving medicines.

Engine Biosciences is a biotech company focused on revolutionizing drug discovery through the application of machine learning and network biomedicine. Based in San Francisco and Asia, the company has developed a proprietary platform that combines high-throughput wet lab experimentation with advanced artificial intelligence algorithms. This platform is designed to map and analyze complex biological networks, generating unique data on gene interactions and providing insights validated through controlled experiments. By doing so, Engine Biosciences aims to accelerate research and development processes and reduce costs associated with creating new medical therapies. The company collaborates with various partners and actively applies its technology to address a range of disease indications, leveraging the expertise of its scientific leadership team, which includes faculty members from renowned institutions such as MIT, Harvard, and the Mayo Clinic.

EpiBiologics focuses on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. The company utilizes its EpiTAC platform to create therapeutics that degrade these disease-driving proteins, addressing the underlying biology of disorders. By specializing in protein degradation, EpiBiologics enables researchers to manipulate cellular proteostasis, offering potential solutions for a wide range of medical conditions.

EpiBiologics focuses on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. The company utilizes its EpiTAC platform to create therapeutics that degrade these disease-driving proteins, addressing the underlying biology of disorders. By specializing in protein degradation, EpiBiologics enables researchers to manipulate cellular proteostasis, offering potential solutions for a wide range of medical conditions.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By exploring the unique aspects of the bat genome, the company aims to identify and develop therapeutics for a variety of diseases. Paratus Sciences seeks to unlock the secrets of bat biology to facilitate innovative treatments, ultimately helping patients combat the health challenges they encounter.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Satellite Bio is a company that specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It is dedicated to developing a therapeutic platform aimed at creating innovative cell therapies to address complex diseases. The company’s primary focus is on the design and implementation of proprietary, off-the-shelf, implantable satellite organs, which serve as living therapeutic solutions. These satellite organs are intended to improve the lives of millions of patients suffering from serious health conditions.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

76Bio is a biotechnology company based in New York that focuses on developing innovative therapies for patients with life-threatening diseases. Founded in 2020, the company specializes in targeted protein degraders, a class of therapeutics designed to selectively degrade unneeded proteins in the body. By leveraging advanced technology, 76Bio aims to create transformational treatments that address critical medical needs, offering hope for improved outcomes in patients suffering from serious health conditions.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Muna Therapeutics is a biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases, such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying new medicines that preserve cognitive function and enhance resilience against these debilitating conditions, thereby providing individuals affected by neurodegenerative diseases with access to effective treatment options. Through its innovative approach, Muna Therapeutics strives to improve the quality of life for those suffering from these challenging disorders.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Engine Biosciences is a biotech company focused on revolutionizing drug discovery through the application of machine learning and network biomedicine. Based in San Francisco and Asia, the company has developed a proprietary platform that combines high-throughput wet lab experimentation with advanced artificial intelligence algorithms. This platform is designed to map and analyze complex biological networks, generating unique data on gene interactions and providing insights validated through controlled experiments. By doing so, Engine Biosciences aims to accelerate research and development processes and reduce costs associated with creating new medical therapies. The company collaborates with various partners and actively applies its technology to address a range of disease indications, leveraging the expertise of its scientific leadership team, which includes faculty members from renowned institutions such as MIT, Harvard, and the Mayo Clinic.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs targeting G protein-coupled receptors (GPCRs). By utilizing its proprietary technology platform, GEODe, Tectonic aims to create therapeutic proteins and antibodies that effectively modulate GPCR activity. The company seeks to address the complexities associated with GPCR-targeted drug discovery, focusing on developing biologic medicines that have the potential to alter disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic is committed to advancing the therapeutic utility of some of the most challenging receptors in this class.

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

IconOVir Bio is a preclinical-stage biotechnology company focused on developing innovative oncolytic virus therapies for cancer treatment. The company's proprietary platform aims to overcome the limitations associated with first- and second-generation oncolytic viruses, thereby enhancing the therapeutic options available to healthcare professionals. By prioritizing personalized therapy, IconOVir Bio seeks to improve treatment outcomes for cancer patients, positioning itself at the forefront of advancements in oncology.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs targeting G protein-coupled receptors (GPCRs). By utilizing its proprietary technology platform, GEODe, Tectonic aims to create therapeutic proteins and antibodies that effectively modulate GPCR activity. The company seeks to address the complexities associated with GPCR-targeted drug discovery, focusing on developing biologic medicines that have the potential to alter disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic is committed to advancing the therapeutic utility of some of the most challenging receptors in this class.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

Satellite Bio is a company that specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It is dedicated to developing a therapeutic platform aimed at creating innovative cell therapies to address complex diseases. The company’s primary focus is on the design and implementation of proprietary, off-the-shelf, implantable satellite organs, which serve as living therapeutic solutions. These satellite organs are intended to improve the lives of millions of patients suffering from serious health conditions.

Invivyd is a biopharmaceutical company committed to developing antibody-based therapies aimed at providing protection against serious viral infectious diseases. The company focuses on creating solutions that go beyond naturally occurring immunity, particularly in response to viral threats with pandemic potential, starting with SARS-CoV-2. Its product pipeline includes ADG20, which is designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody engineered for enhanced potency and broad coverage. By prioritizing rapid and enduring therapeutic options, Invivyd aims to safeguard vulnerable populations from the severe impacts of circulating viral infections.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for cancer immunotherapy. Founded in 2017, the company aims to stimulate innate immunity to enhance the effectiveness of adaptive cancer treatments, such as checkpoint inhibitors. Its TLR7 agonist is designed to activate the immune system by producing cytokines and chemokines that boost cellular responses and facilitate the activation of natural killer cells. This approach enables healthcare providers to target metastatic diseases more effectively and promotes B-cell proliferation and activation, ultimately improving overall response rates and treatment durability for patients.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Montis Biosciences is a biotechnology company based in Meise, Belgium, established in 2020. It focuses on developing immune-oncology therapeutics that address the relationship between vascular dysfunction and immune suppression in the treatment of solid tumors. The company has developed a target screening and assay platform that explores the interactions between tumor endothelial cells and perivascular macrophages. By understanding these cellular interactions, Montis Biosciences aims to create novel therapeutic strategies that enhance immune reactions against solid tumors, offering a new perspective for targeted cancer treatment.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company specializes in soluble guanylate cyclase (sGC) pharmacology to realize the therapeutic potential of next-generation sGC stimulators. Its product pipeline includes Olinciguat, an oral sGC stimulator currently in Phase II trials for sickle cell disease; Praliciguat, also an oral sGC stimulator in Phase II for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, which is in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is engaged in the discovery of liver-targeted and lung-targeted sGC stimulators. Founded in 2018, the company is headquartered in Cambridge, Massachusetts.

Africa Healthcare Network (“AHN”) has established the first dialysis chain across Sub-Saharan Africa, providing high-quality, life-saving dialysis at affordable cost. AHN brings world-class technical expertise combined with developing world practical operating experience to a region in dire need of quality dialysis treatment. Dialysis is a life-saving treatment for patients with Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). The few hospitals that provide treatment operate centers that are slowly deteriorating while charging prohibitive prices. Additionally, the lack of trained professionals and limited capital investment in care for non-communicable diseases in Sub-Saharan Africa, dialysis centers are few and far between, causing patients to endure the high costs for travel to receive care. Those who cannot afford the costs of treatment and travel are resigned to death. Chronic Kidney Disease (CKD) and AKI are on the rise in the region due to strong epidemiologic factors, including increased urbanization leading to lifestyle diseases, other non-communicable diseases, HIV and other infections and toxins. Utilizing our network of executives/partners, we will secure high-quality equipment and train professionals to provide superior care. Our ability to source lowest cost consumables, operational efficiency and scale, will allow us to lower the cost to patients. The net result is increased access, higher quality and lower cost to patients, while maintaining profitability. AHN operates in Rwanda, Tanzania and Kenya.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. The company’s lead products, AL001, AL101, AL002, and AL003, are currently undergoing various stages of clinical trials, with AL001 in a phase II trial for frontotemporal dementia and AL101 in phase I trials targeting multiple neurodegenerative conditions. Alector employs advanced antibody technology combined with insights from neuroimmunology and human genetics to create therapeutics that address underlying disease mechanisms. The company has established a collaboration with Adimab, which specializes in the discovery and optimization of antibody therapeutics, to enhance its research and development efforts. Alector also has several additional programs in the research and development stage, reflecting its commitment to advancing novel treatments for complex neurological disorders. Founded in 2013 and headquartered in South San Francisco, California, Alector aims to restore healthy immune function in the brain through its unique therapeutic approaches.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, focused on developing innovative therapeutic products utilizing its proprietary delivery technology. Founded in 2016, the company specializes in the ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract, eliminating the need for encapsulation. Suono Bio aims to transform the treatment of challenging diseases, particularly those involving inflammatory-mediated conditions, by enabling efficient and effective delivery of therapeutics across various tissues. This technology has the potential to enhance patient recovery from gastrointestinal diseases by ensuring that treatments reach their intended targets quickly and effectively.

Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

Africa Healthcare Network (“AHN”) has established the first dialysis chain across Sub-Saharan Africa, providing high-quality, life-saving dialysis at affordable cost. AHN brings world-class technical expertise combined with developing world practical operating experience to a region in dire need of quality dialysis treatment. Dialysis is a life-saving treatment for patients with Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). The few hospitals that provide treatment operate centers that are slowly deteriorating while charging prohibitive prices. Additionally, the lack of trained professionals and limited capital investment in care for non-communicable diseases in Sub-Saharan Africa, dialysis centers are few and far between, causing patients to endure the high costs for travel to receive care. Those who cannot afford the costs of treatment and travel are resigned to death. Chronic Kidney Disease (CKD) and AKI are on the rise in the region due to strong epidemiologic factors, including increased urbanization leading to lifestyle diseases, other non-communicable diseases, HIV and other infections and toxins. Utilizing our network of executives/partners, we will secure high-quality equipment and train professionals to provide superior care. Our ability to source lowest cost consumables, operational efficiency and scale, will allow us to lower the cost to patients. The net result is increased access, higher quality and lower cost to patients, while maintaining profitability. AHN operates in Rwanda, Tanzania and Kenya.

Genomics Medicine Ireland is an Irish life sciences company leading a large-scale research study across Ireland looking at the human genome to examine the relationship between genetics, health and disease.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. The company’s lead products, AL001, AL101, AL002, and AL003, are currently undergoing various stages of clinical trials, with AL001 in a phase II trial for frontotemporal dementia and AL101 in phase I trials targeting multiple neurodegenerative conditions. Alector employs advanced antibody technology combined with insights from neuroimmunology and human genetics to create therapeutics that address underlying disease mechanisms. The company has established a collaboration with Adimab, which specializes in the discovery and optimization of antibody therapeutics, to enhance its research and development efforts. Alector also has several additional programs in the research and development stage, reflecting its commitment to advancing novel treatments for complex neurological disorders. Founded in 2013 and headquartered in South San Francisco, California, Alector aims to restore healthy immune function in the brain through its unique therapeutic approaches.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. The company’s lead products, AL001, AL101, AL002, and AL003, are currently undergoing various stages of clinical trials, with AL001 in a phase II trial for frontotemporal dementia and AL101 in phase I trials targeting multiple neurodegenerative conditions. Alector employs advanced antibody technology combined with insights from neuroimmunology and human genetics to create therapeutics that address underlying disease mechanisms. The company has established a collaboration with Adimab, which specializes in the discovery and optimization of antibody therapeutics, to enhance its research and development efforts. Alector also has several additional programs in the research and development stage, reflecting its commitment to advancing novel treatments for complex neurological disorders. Founded in 2013 and headquartered in South San Francisco, California, Alector aims to restore healthy immune function in the brain through its unique therapeutic approaches.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, it is focused on discovering and developing innovative genome editing therapeutics to address a wide range of serious diseases. The company utilizes a proprietary platform based on CRISPR/Cas9 technology, which employs a protein-RNA complex to target and modify specific DNA sequences for therapeutic purposes. Editas Medicine aims to translate its advanced genome editing technologies into human therapeutics that can provide precise and corrective molecular modifications to treat genetic disorders. With a strong foundation of patent filings and intellectual property, the company is positioned to advance its early findings into viable treatments for various diseases at the genetic level.

Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

KinDex Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering and developing novel therapeutics for patients suffering from metabolic disorders, including diabetes and obesity. Founded in 2009 and based in Seattle, Washington, the company focuses on compounds that modulate key regulatory networks associated with these conditions. Its lead product, KDT501, is derived from hop extracts and has shown promise in normalizing glucose metabolism and body weight in rodent models. In addition to improving glucose homeostasis, KDT501 may also influence cholesterol and triglyceride levels, reduce body weight gain, and mitigate inflammation linked to metabolic dysfunction. KinDex Pharmaceuticals leverages the Bitter Taste Receptors (TAS2Rs) to target inflammatory and metabolic pathways, aiming to enhance women's health and address chronic diseases.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

Genuity Science is a company that specializes in clinco-omics data analysis solutions for researchers in the fields of central nervous system, cardiometabolic, and inflammatory diseases. The company provides a comprehensive global genomics platform that facilitates the study of biological data insights, offering services that include study design, genomic sequencing, data storage, interpretation, secondary analysis, and scalable analytics. By leveraging the human genome, Genuity Science aims to empower organizations to enhance patient health through advanced genomic insights and analysis.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company’s pipeline includes various NK- and T-cell immuno-oncology programs, such as FT516 for acute myeloid leukemia and B-cell lymphoma, FT596 for B-cell lymphoma and chronic lymphocytic leukemia, and FT538 for multiple myeloma. Additional programs include FT500, FT576, FT819, and FT-ONO1, targeting solid tumors and hematologic malignancies. Fate Therapeutics is also collaborating with Ono Pharmaceutical Co. Ltd. and Janssen Biotech, Inc. to advance its off-the-shelf iPSC-derived CAR T-cell therapies and other innovative treatments. Founded in 2007, the company leverages insights from leading scientists to create and modulate stem cells for therapeutic applications, aiming to restore health through advanced cellular therapies.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company’s pipeline includes various NK- and T-cell immuno-oncology programs, such as FT516 for acute myeloid leukemia and B-cell lymphoma, FT596 for B-cell lymphoma and chronic lymphocytic leukemia, and FT538 for multiple myeloma. Additional programs include FT500, FT576, FT819, and FT-ONO1, targeting solid tumors and hematologic malignancies. Fate Therapeutics is also collaborating with Ono Pharmaceutical Co. Ltd. and Janssen Biotech, Inc. to advance its off-the-shelf iPSC-derived CAR T-cell therapies and other innovative treatments. Founded in 2007, the company leverages insights from leading scientists to create and modulate stem cells for therapeutic applications, aiming to restore health through advanced cellular therapies.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company’s pipeline includes various NK- and T-cell immuno-oncology programs, such as FT516 for acute myeloid leukemia and B-cell lymphoma, FT596 for B-cell lymphoma and chronic lymphocytic leukemia, and FT538 for multiple myeloma. Additional programs include FT500, FT576, FT819, and FT-ONO1, targeting solid tumors and hematologic malignancies. Fate Therapeutics is also collaborating with Ono Pharmaceutical Co. Ltd. and Janssen Biotech, Inc. to advance its off-the-shelf iPSC-derived CAR T-cell therapies and other innovative treatments. Founded in 2007, the company leverages insights from leading scientists to create and modulate stem cells for therapeutic applications, aiming to restore health through advanced cellular therapies.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Avila Therapeutics is focused on designing and developing covalent drugs aimed at treating viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule that acts as a protease inhibitor for hepatitis C virus. Founded in 2006 and based in Waltham, Massachusetts, Avila Therapeutics operates as a subsidiary of Celgene Corporation, following its acquisition in 2012. The company has also established a strategic alliance with Sanofi-Aventis to enhance its research and development efforts.

Adnexus, a Bristol-Myers Squibb R&D Company, is leading the discovery and development of Adnectinsâ„¢, a novel, proprietary class of targeted biologics. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to fight diseases across a broad range of therapeutic areas. Their proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines. Adnexus, a Bristol-Myers Squibb R&D Company, is a leader in the discovery and development of Adnectins, a proprietary type of targeted biologic. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to help fight diseases across a broad range of therapeutic areas. Our proprietary technology for engineering these proteins creates an opportunity to rapidly generate compounds for study as potential treatment options for patients. Targeted biologics are one of the most medically important and fastest growing areas in the biopharmaceutical industry. These drugs are specifically designed to attack targets of disease. Despite the success of the first generation targeted therapeutic products, such as antibodies, additional innovations are sought by the medical community to help meet unmet needs for improved safety, and efficacy. We believe the study of Adnectins can help to address these demands. Adnectins are derived from human fibronectin, an abundant extracellular protein that binds naturally to a number of different proteins. We create Adnectins using our proprietary protein engineering system called PROfusion™. Our scientists can rapidly create PROfusion libraries of more than 10 trillion different Adnectins. We then screen these libraries to identify Adnectins with the desired drug properties against therapeutic targets of interest. PROfusion enables discovery productivity by minimizing the timeframe for identifying high-quality candidates. In October 2007, Adnexus was acquired by Bristol-Myers Squibb Company. This acquisition has further accelerated our growth as an industry leader in the discovery and early development of proprietary targeted biologics. Together with Bristol-Myers Squibb, we are developing multiple Adnectin programs for use in the study of potential treatments in a broad range of disease types, including oncology, immunology, and cardiovascular disease.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Adnexus, a Bristol-Myers Squibb R&D Company, is leading the discovery and development of Adnectinsâ„¢, a novel, proprietary class of targeted biologics. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to fight diseases across a broad range of therapeutic areas. Their proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines. Adnexus, a Bristol-Myers Squibb R&D Company, is a leader in the discovery and development of Adnectins, a proprietary type of targeted biologic. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to help fight diseases across a broad range of therapeutic areas. Our proprietary technology for engineering these proteins creates an opportunity to rapidly generate compounds for study as potential treatment options for patients. Targeted biologics are one of the most medically important and fastest growing areas in the biopharmaceutical industry. These drugs are specifically designed to attack targets of disease. Despite the success of the first generation targeted therapeutic products, such as antibodies, additional innovations are sought by the medical community to help meet unmet needs for improved safety, and efficacy. We believe the study of Adnectins can help to address these demands. Adnectins are derived from human fibronectin, an abundant extracellular protein that binds naturally to a number of different proteins. We create Adnectins using our proprietary protein engineering system called PROfusion™. Our scientists can rapidly create PROfusion libraries of more than 10 trillion different Adnectins. We then screen these libraries to identify Adnectins with the desired drug properties against therapeutic targets of interest. PROfusion enables discovery productivity by minimizing the timeframe for identifying high-quality candidates. In October 2007, Adnexus was acquired by Bristol-Myers Squibb Company. This acquisition has further accelerated our growth as an industry leader in the discovery and early development of proprietary targeted biologics. Together with Bristol-Myers Squibb, we are developing multiple Adnectin programs for use in the study of potential treatments in a broad range of disease types, including oncology, immunology, and cardiovascular disease.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

GlycoFi is a biotech firm based in Lebanon, New Hampshire, focused on developing biotherapeutics through its innovative glycan optimization technology. The company has engineered a library of yeast strains that enable precise human glycosylation, resulting in therapeutic proteins suitable for drug development. GlycoFi aims to establish its own pipeline of therapeutic products while also collaborating with other pharmaceutical companies to enhance their drug offerings. Founded in 2000, GlycoFi operates as a subsidiary of Merck & Co., Inc., further expanding its capabilities in the biotherapeutics landscape.